At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial ...

In this special edition of the Student Notebook, early-career scholars from across the APSSC community share their ...

From this core mechanism Fc engineering has evolved over time into the "engine" of therapeutic antibody development. It enables precise modulation of immune effector functions, optimization of ...

ENS-002 was safe and well-tolerated with no drug-related adverse events, meeting its primary endpoint. Secondary endpoints were positive: eczema symptoms improved, and Staphylococcus aureus (S. aureus ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

In August, 2025, the US Food and Drug Administration (FDA) published a draft guidance on the assessment of overall survival ...

Consistent duration of response was observed across PD-L1–positive and negative tumors, as well as in both primary and secondary resistance settings. Median duration of response for PD-L1-negative ...

TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73 billion (USD 11.6 million 1) in four R&D projects ...

Introduction Stress is a major health issue in contemporary society, and mindfulness-based approaches reduce stress and anxiety but face practical barriers to consistent practice; this protocol ...

Research reveals that brief, structured micro-breaks, under ten minutes, significantly enhance student attention and learning ...